About Champions Oncology (NASDAQ:CSBR)
Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides Personalized Oncology Solutions (POS) that assist physicians in developing personalized treatment options for cancer patients through tumor specific data obtained from drug panels and related personalized oncology services. The company also offers POS products, including personalized tumor boards that are designed to provide access to oncologists with expertise in particular tumor types; and provides access to gene sequencing that analyzes the genetic makeup of patient's tumor for the purpose of identifying potentially useful drugs. In addition, it offers Translational Oncology Solutions (TOS), including a preclinical Tumorgraft platform to pharmaceutical and biotechnology companies that use vivo studies, which rely on implanting multiple tumors from TumorBank in mice and testing the therapy of interest on tumors. The company markets its products through Internet, word of mouth, and a network of sales force to patients and physicians. Champions Oncology, Inc. has collaboration agreements with The Addario Lung Cancer Medical Institute and AstraZeneca to develop cohorts of PDX models. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011 to reflect its new focus on developing technologies to personalize the development and use of oncology drugs. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Annual Sales$15.41 million
Price / Sales2.80
Price / CashN/A
Book Value$0.04 per share
Price / Book98.00
EPS (Most Recent Fiscal Year)N/A
Return on Equity-854.38%
Return on Assets-46.60%
Champions Oncology (NASDAQ:CSBR) Frequently Asked Questions
What is Champions Oncology's stock symbol?
Champions Oncology trades on the NASDAQ under the ticker symbol "CSBR."
How were Champions Oncology's earnings last quarter?
Champions Oncology, Inc. (NASDAQ:CSBR) released its earnings results on Thursday, March, 15th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter. The biotechnology company had revenue of $5.08 million for the quarter. Champions Oncology had a negative return on equity of 854.38% and a negative net margin of 17.17%. View Champions Oncology's Earnings History.
Who are some of Champions Oncology's key competitors?
Some companies that are related to Champions Oncology include Pluristem Therapeutics (PSTI), Organovo (ONVO), Eiger Biopharmaceuticals (EIGR), Aptose Biosciences (APTO), Krystal Biotech (KRYS), Applied Genetic Technologies (AGTC), Aevi Genomic Medicine (GNMX), Curis (CRIS), Cidara Therapeutics (CDTX), aTyr Pharma (LIFE), Genocea Biosciences (GNCA), Brainstorm Cell Therapeutics (BCLI), TRACON Pharmaceuticals (TCON), CytRx (CYTR) and BiondVax (BVXV).
Who are Champions Oncology's key executives?
Champions Oncology's management team includes the folowing people:
- Dr. Ronnie Morris M.D., CEO & Director (Age 52)
- Mr. David Barry Miller, Chief Financial Officer (Age 49)
- Dr. Philip P. Breitfeld, Chief Strategy & Innovation Officer and Director (Age 65)
- Mr. Mark Weinstein, Chief Information Officer
- Dr. Angela M. Davies M.D., FRCPC, Chief Medical Officer (Age 48)
Has Champions Oncology been receiving favorable news coverage?
Press coverage about CSBR stock has been trending somewhat positive this week, according to Accern Sentiment. The research firm scores the sentiment of media coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Champions Oncology earned a daily sentiment score of 0.08 on Accern's scale. They also gave news stories about the biotechnology company an impact score of 46.53 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near future.
How do I buy shares of Champions Oncology?
Shares of CSBR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Champions Oncology's stock price today?
One share of CSBR stock can currently be purchased for approximately $3.92.
How big of a company is Champions Oncology?
Champions Oncology has a market capitalization of $44 million and generates $15.41 million in revenue each year. Champions Oncology employs 79 workers across the globe.
How can I contact Champions Oncology?
Champions Oncology's mailing address is One University Plaza Suite 307, Hackensack NJ, 07601. The biotechnology company can be reached via phone at 201-808-8400 or via email at [email protected]
MarketBeat Community Rating for Champions Oncology (CSBR)MarketBeat's community ratings are surveys of what our community members think about Champions Oncology and other stocks. Vote "Outperform" if you believe CSBR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CSBR will underperform the S&P 500 over the long term. You may vote once every thirty days.
Champions Oncology (NASDAQ:CSBR) Analyst Ratings History
(Data available from 4/25/2016 forward)
|Date||Brokerage||Action||Rating||Price Target||Impact on Share Price||Details|
Champions Oncology (NASDAQ:CSBR) Earnings History and Estimates Chart
Champions Oncology (NASDAQ CSBR) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|3/15/2018||Q3 2018||($0.01)||$5.08 million||View||Listen|
|12/7/2017||Q2 2018||($0.01)||$5.20 million||View||Listen|
|9/14/2017||Q1 2018||($0.06)||$5.03 million||View||N/A|
|7/27/2017||Q4 2017||($0.22)||$3.72 million||View||N/A|
|3/16/2017||Q3 2017||($0.13)||$3.57 million||View||N/A|
|11/29/2016||Q2 2017||($0.05)||$4.46 million||View||N/A|
|9/9/2016||Q1 2017||($0.26)||$3.67 million||View||N/A|
|7/28/2016||Q4 2016||($0.30)||$2.84 million||View||N/A|
|3/15/2016||Q316||($0.21)||$1.80 million||$2.60 million||View||Listen|
|12/14/2015||Q2 2016||($0.29)||$2.97 million||View||N/A|
|9/10/2015||Q1 2016||($0.33)||$2.82 million||View||N/A|
|7/28/2015||Q4 2015||($0.60)||$3.24 million||View||N/A|
|3/17/2015||Q3 2015||($0.48)||$1.83 million||View||N/A|
|12/12/2014||Q2 2015||($0.60)||$1.88 million||View||N/A|
|9/11/2014||Q1 2015||($0.60)||$1.91 million||View||N/A|
|7/24/2014||Q4 2014||($0.36)||$2.46 million||View||N/A|
|3/13/2014||Q3 2014||($0.12)||$3.69 million||View||N/A|
|12/12/2013||Q1 14||($0.03)||$2.38 million||View||N/A|
|7/26/2013||Q4 2013||($0.36)||$1.84 million||View||N/A|
|3/14/2013||Q3 13||($0.01)||$2.92 million||View||N/A|
Champions Oncology (NASDAQ:CSBR) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Champions Oncology (NASDAQ CSBR) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 44.30%
Institutional Ownership Percentage: 37.85%
Champions Oncology (NASDAQ CSBR) Insider Trading History
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|3/27/2018||Ronnie Morris||CEO||Buy||4,535||$3.59||$16,280.65||1,114,282|| |
|3/22/2018||Ronnie Morris||CEO||Buy||260||$3.49||$907.40||1,111,407|| |
|10/21/2016||Ronnie Morris||President||Buy||30,000||$1.66||$49,800.00||1,091,347|| |
|10/19/2016||Ronnie Morris||President||Buy||10,000||$1.70||$17,000.00||1,081,347|| |
|10/18/2016||Joel Ackerman||CEO||Buy||2,000||$1.70||$3,400.00||1,043,266|| |
|10/14/2016||Joel Ackerman||CEO||Buy||7,300||$1.67||$12,191.00||1,035,466|| |
|10/14/2016||Ronnie Morris||President||Buy||10,305||$1.66||$17,106.30||1,061,347|| |
|10/13/2016||Ronnie Morris||President||Buy||29,695||$1.67||$49,590.65||1,041,347|| |
|10/10/2016||Ronnie Morris||President||Buy||9,537||$1.66||$15,831.42||1,026,347|| |
|10/7/2016||Joel Ackerman||CEO||Buy||8,202||$1.63||$13,369.26||1,027,764|| |
|9/23/2016||Joel Ackerman||CEO||Buy||33||$1.65||$54.45||1,026,764|| |
|9/21/2016||Joel Ackerman||CEO||Buy||5,000||$1.66||$8,300.00||1,022,731|| |
|9/20/2016||Ronnie Morris||President||Buy||3,000||$1.58||$4,740.00||1,021,810|| |
|3/11/2015||Michael Maurice Brown||Major Shareholder||Buy||6,250,000||$0.40||$2,500,000.00|| |
|3/20/2014||Daniel Newman Mendelson||Director||Buy||100,000||$1.08||$108,000.00|| |
|3/19/2014||Ronnie Morris||President||Buy||100,000||$1.07||$107,000.00|| |
|1/28/2013||Michael Maurice Brown||Major Shareholder||Buy||7,000,000||$0.50||$3,500,000.00|| |
|1/28/2013||Ronnie Morris||President||Buy||500,000||$0.50||$250,000.00|| |
Champions Oncology (NASDAQ CSBR) News Headlines
|Champions Oncology to Present at The MicroCap Conference on April 10th in New York City at the Essex House|
finance.yahoo.com - April 4 at 5:32 PM
|Insider Buying: Champions Oncology Inc (CSBR) CEO Acquires 4,535 Shares of Stock|
www.americanbankingnews.com - March 28 at 11:10 PM
|Champions Oncology (CSBR) Issues Quarterly Earnings Results|
www.americanbankingnews.com - March 16 at 9:28 AM
|Champions Oncology, Inc. to Host Earnings Call|
finance.yahoo.com - March 15 at 4:29 PM
|Champions Oncology Reports Quarterly Revenue of $5.1 Million|
finance.yahoo.com - March 15 at 4:29 PM
|Does Champions Oncology Inc’s (NASDAQ:CSBR) Past Performance Indicate A Stronger Future?|
finance.yahoo.com - March 15 at 9:55 AM
|Champions Oncology (CSBR) to Release Earnings on Thursday|
www.americanbankingnews.com - March 8 at 8:16 PM
|Champions Oncology to Announce Third Quarter Financial Results on Thursday, March 15, 2018|
finance.yahoo.com - March 7 at 10:12 AM
|How Financially Strong Is Champions Oncology Inc (NASDAQ:CSBR)?|
finance.yahoo.com - February 28 at 9:56 AM
|Champions Oncology to Participate at the 30th Annual ROTH Conference|
finance.yahoo.com - February 26 at 9:54 AM
|Motivated Patients with ROS1 Cancer Initiate Global Research Study|
finance.yahoo.com - February 21 at 10:25 AM
|February Insights Into Healthcare Stocks: Champions Oncology Inc (NASDAQ:CSBR)|
finance.yahoo.com - February 15 at 9:06 AM
|Why Champions Oncology Inc’s (NASDAQ:CSBR) CEO Pay Matters To You|
finance.yahoo.com - December 30 at 9:07 AM
|Champions Oncology, Inc. :CSBR-US: Earnings Analysis: Q2, 2018 By the Numbers : December 19, 2017|
finance.yahoo.com - December 19 at 5:35 PM
|Blog Exposure - FDA Granted Tentative Approval for Expanded Label for Egalet’s ARYMO ER Extended-Release Tablets C-II|
finance.yahoo.com - December 18 at 9:23 AM
|Champions Oncology (CSBR) Announces Earnings Results|
www.americanbankingnews.com - December 8 at 9:28 AM
|Champions Oncology Reports Record Quarterly Revenue of $5.2 Million|
finance.yahoo.com - December 7 at 6:07 PM
|Was Champions Oncology Inc’s (CSBR) Earnings Growth Better Than Industry?|
finance.yahoo.com - December 7 at 9:16 AM
|ValuEngine Downgrades Champions Oncology (CSBR) to Sell|
www.americanbankingnews.com - December 6 at 11:26 PM
|Champions Oncology (CSBR) Set to Announce Quarterly Earnings on Thursday|
www.americanbankingnews.com - November 30 at 1:50 AM
|Champions Oncology to Announce Second Quarter Financial Results on Thursday, December 7, 2017|
finance.yahoo.com - November 28 at 8:35 AM
|Champions Oncology Inc (CSBR): Time For A Financial Health Check|
finance.yahoo.com - November 27 at 6:10 PM
|Champions Oncology to Present at 10th Annual Main Event on December 5|
finance.yahoo.com - November 27 at 6:10 PM
|Champions Oncology, Inc. (CSBR) Scheduled to Post Quarterly Earnings on Monday|
www.americanbankingnews.com - November 20 at 1:40 AM
Champions Oncology (NASDAQ:CSBR) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Champions Oncology (NASDAQ:CSBR) Income Statement, Balance Sheet and Cash Flow Statement
Champions Oncology (NASDAQ CSBR) Stock Chart for Wednesday, April, 25, 2018